Clinical Trial Update: Bioequivalence of Two Different Sources of Eslicarbazepine Acetate [Phase 1]

View source ↗

Summary

Phase 1 bioequivalence study comparing eslicarbazepine acetate from two different sources in epilepsy patients to establish similar pharmacokinetic profiles.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Epilepsy

Drugs mentioned

• eslicarbazepine acetate (eslicarbazepine acetate)

Snippet

Sponsor: Bial - Portela C S.A. | Conditions: Epilepsy | Phase 1 | Status: COMPLETED